SCHEMBL3874883

SCHEMBL3874883

CC(=O)Nc1nc(C)c(S(=O)(=O)Nc2ccc3[nH]c4c(c3c2)CCN(C)C4)s1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RORA P35398 1/20 0.47
RORC P51449 1/20 0.47
RORB Q92753 1/20 0.47
MAPT P10636 9/20 0.45
HTR1A P08908 2/20 0.42
HTR2C P28335 2/20 0.42
HTR7 P34969 2/20 0.42
HTR6 P50406 2/20 0.42
TP53 P04637 7/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 1/20 0.39
BAZ2B Q9UIF8 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
ITK Q08881 1/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CG P48736 1/20 0.37
PIK3C3 Q8NEB9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3873167 0.81 MAPT (0.63) MAPTHTR1AHTR2CHTR7HTR6
SCHEMBL3874098 0.75 HTR6 (0.60) HTR1AHTR2CHTR7HTR6
SCHEMBL3879041 0.74 KIT (0.48) MAPTHTR1AHTR2CHTR7HTR6
SCHEMBL3874868 0.73 HTR6 (0.57) MAPTHTR1AHTR2CHTR7HTR6
SCHEMBL4022862 0.72 HTR6 (0.59) MAPTHTR1AHTR2CHTR7HTR6
SCHEMBL4024729 0.72 HTR6 (0.56) HTR1AHTR2CHTR7HTR6KDM4E
SCHEMBL4026117 0.72 HTR6 (0.55) HTR6
SCHEMBL12316100 0.72 HTR2C (0.56) MAPTHTR1AHTR2CHTR7HTR6
Hydrochloric Acid SCHEMBL4031202 0.72 HTR6 (0.60) MAPTHTR1AHTR2CHTR7HTR6
SCHEMBL12316095 0.71 HTR2C (0.55) MAPTHTR1AHTR2CHTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US claimed
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US claimed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP claimed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP claimed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US claimed
EP-1747779-A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-31 EP claimed
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US disclosed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP disclosed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP disclosed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed
WO-2007028460-A1 TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-15 WO disclosed
EP-1747779-A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-31 EP disclosed
EP-1747779-A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264457-A1 Combination of at least two 5HT6-Ligands HTR6, HTR3B, HTR4 RORA 3097/4885RORC 3523/4885RORB 3088/4885
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands HTR6, HTR5A, HTR1B RORA 534/4885RORC 660/4885RORB 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.